Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Schoppe

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
Schizophrenia Research|August 29, 1997
Olfactory identification deficit in relation to schizotypyS Park, S Schoppe
Multiple Sclerosis (Houndmills, Basingstoke, England)|March 6, 2003
Effect of immunomodulatory drugs on in vitro production of brain-derived neurotrophic factorH F Petereit, H Lindemann, S Schoppe
Acta Neurologica Scandinavica|September 6, 2003
The immunomodulatory properties of in vitro immunoglobulins are dose-dependentD Reske, S Schoppe, C Broicher, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|December 12, 2002
Low interferon gamma producers are better treatment responders: a two-year follow-up of interferon beta-treated multiple sclerosis patientsH F Petereit, S Nolden, S Schoppe, et al.
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
Schizophrenia Research|August 29, 1997
Olfactory identification deficit in relation to schizotypyS Park, S Schoppe
Multiple Sclerosis (Houndmills, Basingstoke, England)|March 6, 2003
Effect of immunomodulatory drugs on in vitro production of brain-derived neurotrophic factorH F Petereit, H Lindemann, S Schoppe
Acta Neurologica Scandinavica|September 6, 2003
The immunomodulatory properties of in vitro immunoglobulins are dose-dependentD Reske, S Schoppe, C Broicher, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|December 12, 2002
Low interferon gamma producers are better treatment responders: a two-year follow-up of interferon beta-treated multiple sclerosis patientsH F Petereit, S Nolden, S Schoppe, et al.
Pageof 1